atorvastatin/fenofibrate / Generic mfg. - LARVOL DELTA

Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia. (PubMed, Cardiol Ther) - P3 | "The FDC therapy of atorvastatin 20 mg/fenofibrate 160 mg achieved a greater percentage reduction in lipid profile than atorvastatin alone. No differences in adverse events were observed between the groups."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Mixed Hyperlipidemia • Type 2 Diabetes Mellitus

When Metabolic Stress Meets Genetics: A Triad of DKA, Acute Pancreatitis, and Hypertriglyceridemia in a Patient with LMF1 Mutation (ENDO 2025) - "He had poor adherence to metformin, Jardiance, and pioglitazone, with an A1C of 10.7%...He was discharged on insulin, atorvastatin, and fenofibrate with a diabetes education referral...Plasmapheresis may be more effective in LPL deficiency cases, warranting further research in the future.*. .*"

Clinical • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • LPL

Giant Pancreatic Pseudocyst as a complication of Hypertriglyceridemia-Induced Pancreatitis (ENDO 2025) - "On day tenth, given clinical and biochemical improvement and a multidisciplinary team discussion, patient was discharged on metformin, fenofibrate, atorvastatin, pioglitazone, and vascepa, with plan for GI follow-up for possible necrosectomy. This case reports rare occurrence of HTG-induced necrotizing pancreatitis with the formation of giant pancreatic pseudocyst. It also illustrates the importance of timely intervention and proper management of severe hypertriglyceridemia, to reduce the risk of complications including necrotizing pancreatitis and pseudocyst. Long-term management should be focused on alleviating the effects of metabolic syndrome by addressing related factors like diabetes and obesity."

Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pain • Pancreatitis • Severe Hypertriglyceridemia

LIPOPROTEIN GLOMERULOPATHY WITH NOVEL GENETIC VARIANT- CASE REPORT (ISN-WCN 2025) - "Diagnosis of nephrotic syndrome was made and he was started on prednisolone 2mg/kg/day, Furosemide and advised fluid and salt restriction...Immunosuppression was stopped and child was treated with atorvastatin 20mg + Fenofibrate 80mg, Telmisartan 20mg once daily...To our knowledge, this APOE mutation c.502C>T (p. Arg168Cys) has not been reported in literature and is the youngest patient to develop this disease."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hypertension • Metabolic Disorders • Pediatrics • Rare Diseases • APOE • ARG1

Capecitabine-Induced Hypertriglyceridemia Leading to Pancreatitis: A Rare Presentation (ACG 2024) - "Case Description/ A 36-year-old female with ER/PR receptor-negative invasive ductal carcinoma of the breast on pembrolizumab, carboplatin, and capecitabine, presented to the emergency department with epigastric pain...Initiation of fenofibrate and atorvastatin further reduced her triglyceride level to 591 mg/dL six days post-presentation when she was discharged...Figure: Figure 1: Computed Tomography (CT) scan showing acute interstitial edematous pancreatitis. (A) Coronal view; (B) Sagittal view."

Breast Cancer • Dyslipidemia • Gastrointestinal Disorder • Hypertriglyceridemia • Oncology • Pain • Pancreatitis • Solid Tumor

Enhancing intracellular cholesterol efflux in chondrocytes alleviates osteoarthritis progression. (PubMed, Arthritis Rheumatol) - "Our results suggest that restoration of cholesterol homeostasis to a normal state through administration of fenofibrate or AIBP overexpression, both of which induce cholesterol efflux, offers an effective therapeutic option for OA."

Journal • Dyslipidemia • Immunology • Osteoarthritis • Pain • Rheumatology • APOA1

Reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Treated with a Fixed-Dose Combination of Atorvastatin/Fenofibrate (ADA 2024) - "Patients receiving Atorvastatin/Fenofibrate FDC had a better reduction than monotherapy in non-LDL cholesterol-dependent RRL markers, which translates to a decrease in overall cardiovascular risk for this treatment group."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome (NLA 2024) - "Prior to discharge, she was restarted on atorvastatin, fenofibrate, and omega-3 acid ethyl esters. Managing severe, symptomatic HTG includes NPO status, insulin infusion, and oral lipid lowering therapies; often requiring prolonged hospitalization. Plasmapheresis, though costly and invasive, offers a rapid reduction in TG, symptom resolution, and prevention of HTG-associated complications. Future studies on these treatment modalities can aid in developing inpatient management guidelines for chylomicronemia syndrome."

Cardiovascular • Dyslipidemia • Hypertension • Hypertriglyceridemia • Pain • Pancreatitis • Type 2 Diabetes Mellitus

Triglyceride Tango: when Triglycerides take legs for a spin (ENDO 2024) - "IV fluids were started, and the patient received IV Dilaudid for pain...Endocrine was consulted and recommended initiation of a fenofibrate and atorvastatin. Although the patient was not a diabetic, endocrinology gave 20 units of basal insulin to the patient (Lantus)...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis

TREATMENT OF HYPERTRIGLYCERIDEMIA INDUCED PANCREATITIS (ENDO 2024) - "Hydromorphone and ketorolac used for pain...Patient was discharged back home on hospital day 5 with fenofibrate, atorvastatin, thiamine, and folic acid.Conclusion : This case report serves as a valuable learning experience by showcasing the interplay of risk factors, the importance of diligent treatment, and the effectiveness of prompt and multi-faceted management of triglyceride-induced pancreatitis...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Diabetes • Dyslipidemia • Gastroenterology • Hepatology • Hypertriglyceridemia • Hypoglycemia • Metabolic Disorders • Pain • Pancreatitis • Psychiatry

The Interplay Between Hypertriglyceridemia and Pancreatogenic Diabetes Mellitus (ENDO 2024) - "She is being managed with insulin glargine, insulin aspart, metformin, pancrelipase, fenofibrate, atorvastatin, and omega-3 polyunsaturated fatty acid; however, her triglyceride level remains high at 5,353 mg/dL and diabetes remains uncontrolled with most recent HbA1c of 9%. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Neuropathy • Dyslipidemia • Gastroenterology • Hematological Disorders • Hepatology • Hypertriglyceridemia • Immunology • Inflammation • Lipodystrophy • Metabolic Disorders • Nephrology • Pain • Pancreatitis • Polycystic Ovary Syndrome • Renal Disease • Retinal Disorders • Substance Abuse • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • HNF1A

Clinical Analysis of Atorvastatin Calcium, Fenofibrate, and Acipimox in the Treatment of Hypertriglyceridemia-induced Acute Pancreatitis. (PubMed, Altern Ther Health Med) - "The patients were grouped: atorvastatin calcium, acipimox, fenofibrate, fenofibrate + Atorvastatin calcium, fenofibrate + acipimox, and no drug. Moreover, this study provides valuable insights into the management of HTG-AP and suggests that lipid-lowering agents, such as atorvastatin calcium and fenofibrate, play a crucial role in the treatment of this condition. However, further research is needed to explore the optimal dosages, treatment durations, and potential side effects of these medications in HTG-AP patients."

Journal • Dyslipidemia • Gastrointestinal Disorder • Hypertriglyceridemia • Hypotension • Infectious Disease • Inflammation • Pain • Pancreatitis • CRP

A novel mouse model of familial combined hyperlipidemia and atherosclerosis. (PubMed, Acta Pharmacol Sin) - "Oral administration of atorvastatin and fenofibrate significantly decreased the plaque sizes of en face aorta, aortic sinus and innominate artery accompanied by improved lipid profile and distribution. In summary, this novel mouse model is of considerable clinical relevance for evaluation of anti-atherosclerotic drugs by targeting both hypercholesterolemia and hypertriglyceridemia."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • APOC3

“Oh Sweet Pancreas of Mine”: A Case of SGLT2 Inhibitor Euglycemic DKA in the Setting of Antipsychotic Induced Hypertriglyceridemia Causing Acute Pancreatitis (ACG 2023) - "The patient started empagliflozin and metformin one week ago...The patient was discharged on a regimen of insulin, atorvastatin, fenofibrate and haloperidol...SGLT2-induced eDKA is well reported, and in our patient HTG-AP may have led to eDKA from recent empagliflozin use. This case brings to light the importance of recognizing the risk associated with these medications and its subsequent successful management in a critically ill patient."

Clinical • CNS Disorders • Diabetes • Dyslipidemia • Hypertriglyceridemia • Pain • Pancreatitis • Psychiatry • Schizophrenia • LPL

Audio/Podcasts and Art: A Collaboration Between the Renal Patient Support Group (RPSG) and the Kidney Disease and Renal Support Group (KDARs) for Kids and ZtormLabostix Productions (KIDNEY WEEK 2023) - "Case Description 60-year-old woman with diabetes mellitus type 2, hypertension, hyperlipidemia, chronic osteoarthritis, chronic pelvic pain, and history of rheumatic heart fever was referred for intermittent hypercalcemia, ranging between 9.9-11.2 mg/dL.Medications: amlodipine, atorvastatin, fenofibrate, glimerpiride, metformin, metoprolol, magnesium oxide, loratidine.Vital signs: height 160 cm, weight 85.5 kg, blood pressure 145/62 mmHg, pulse 72 bpm, 36.2oC.Physical exam: within normal limits.Other laboratory findings: Serum phosphorus ranges between 2.6-3.8 mg/dL (2.4-4.7 mg/dL), albumin 4.1 g/dL (3.5-4.8 g/dL), PTHrp 16 pg/mL, (14-27 pg/mL), 1,25D3 ranges between 67-82 pg/mL (18-72), PTH ranges between 28-49 pg/mL (15-65). Hypercalcemia has a wide differential diagnosis. A thorough search for its cause is warranted for direct and specific therapy."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Gastrointestinal Disorder • Gynecology • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Osteoarthritis • Pain • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

Fixed Combination for the Treatment of Dyslipidaemia. (PubMed, Curr Atheroscler Rep) - "The fixed-dose combination of bempedoic acid with ezetimibe is superior to bempedoic acid in monotherapy in lowering LDL-C and in reducing high-sensitivity C-reactive protein concentrations. The combination fenofibrate with atorvastatin is superior to monotherapies in lowering triglycerides. Lipid-lowering fixed-dose combinations may guarantee a higher therapy adherence, representing a better approach to control plasma lipids and thus ameliorate ASCVD burden. Additional studies will define the advantages on cardiovascular outcomes in high and very high-risk patients."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • CRP

Marked Reduction in Severe Resistant Hypertriglyceridemia on PCSK9 Inhibitor (ENDO 2023) - "Past medical history was significant for recurrent pancreatitis and diabetes mellitus type 2 with recent HbA1c of 7.6% (normal range <5.7%) on metformin 1 gram BID and insulin glargine 15 units daily...His triglycerides remained elevated on fenofibrate, atorvastatin, and icosapent ethyl despite alcohol avoidance and changes in diet with progressive elevation to 5000 mg/dL (normal range 0-150 mg/dL) requiring four sessions of plasmapheresis and hospitalization requiring intravenous insulin drip... This is the first reported case of an unexplored potential of evolocumab in patients with severe hypertriglyceridemia."

Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Tamoxifen-Induced Hypertriglyceridemia Causing Acute Pancreatitis (ACG 2022) - "Tamoxifen was discontinued and the patient was started on fenofibrate and atorvastatin. This case suggests that those on tamoxifen should have regular monitoring of serum lipids and treat any abnormal lab value as significant until proven otherwise. Figure: Inflammatory change in the pancreatic head region is suggestive of acute pancreatitis."

Breast Cancer • Dyslipidemia • Gastroenterology • Hepatology • Hormone Receptor Breast Cancer • Hypertriglyceridemia • Inflammation • Oncology • Pain • Pancreatitis • Solid Tumor

Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation. (PubMed, Cancers (Basel)) - "Moreover, we investigated the efficacy of cholesterol-lowering medications, such as cholestyramine, fenofibrate, and atorvastatin, in regulating LCPF-regulated angiogenesis. A Kaplan-Meier analysis revealed the clinical benefit of statin exposure in patients with lung adenocarcinoma with LCPF. Conclusively, our study demonstrated the ability of statin to alleviate LCPF-induced angiogenesis in patients with LCPF via FXR modulation."

Journal • Gastrointestinal Cancer • Gastrointestinal Disorder • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus. (PubMed, Cureus) - "In Group I (atorvastatin + fenofibrate), the mean cholesterol at 24-week follow-up was 254.51 ± 47.41 as compared to 230.45 ± 47.21 in Group II (p<0.0001). Similarly, total triglycerides, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) were significantly higher in Group I patients by 24-week follow-up as compared to Group II. The mean HDL levels in Group I changed from 40.21 ± 3.54 at baseline to 46.28 ± 6.25 at follow-up, while in Group II, the mean HDL levels altered from 39.54 ± 4.52 to 52.34 ± 7.54 (p<0.0001).  Conclusion Overall, both groups showed significant improvements in lipid profiles; however, when atorvastatin in addition to fenofibrate was compared with saroglitazar, it was found that the latter combination was more effective in improving the overall patient outcome."

Journal • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP. (clinicaltrials.gov) - P3 | N=78 | Recruiting | Sponsor: Laboratorios Silanes S.A. de C.V. | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2022 ➔ May 2022 | Initiation date: Jun 2021 ➔ Feb 2022 | Trial primary completion date: Sep 2021 ➔ May 2022

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Plasmapheresis in Pancreatitis Secondary to Severe Hypertriglyceridemia (ACG 2021) - "She takes atorvastatin, fenofibrate and omega-3-acid ethyl esters, with most recent TG level of 775mg/dL. Factors Affecting Outcome in Acute Hypertriglyceridemic Pancreatits treated with plasma exchange: An Obesrvational Cohort Study. 2014"

Dyslipidemia • Hypertriglyceridemia • Hypoglycemia • Pain • Pancreatitis

[VIRTUAL] COVID-19 PRECIPITATING ACUTE PANCREATITIS? A CASE REPORT (CHEST 2021) - "CASE PRESENTATION: A 45-year-old overweight woman with body mass index (BMI) of 26.91kg/m2 was admitted to an outside hospital for 1.5 weeks with COVID-19 infection for which she received azithromycin and 4 mg dexamethasone daily...Later she received gemfibrozil and atorvastatin. She was transferred out of intensive care unit on Day 7 and switched to long-acting insulin, fenofibrate, and atorvastatin at discharge... Screening of DKA patients for lipid levels with abdominal imaging in patients with persistent abdominal pain despite correction of acidosis may prevent a delay the diagnosis of this fatal triad"

Clinical • Cardiovascular • Critical care • Diabetes • Dyslipidemia • Hepatology • Hypertriglyceridemia • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Pain • Pancreatitis • Pneumonia • Respiratory Diseases

Novel Therapies for Kidney Disease in People with Diabetes. (PubMed, J Clin Endocrinol Metab) - "Trials have yielded promising results in the search for new therapies to manage DKD. Sodium-glucose cotransporter-2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes. Mineralocorticoid-receptor antagonists are another class of agents with increasing evidence of benefits."

Journal • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Ophthalmology • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. (PubMed, Biomed Pharmacother) - "Moreover, intravenous administration of PL nanoparticles restored lipid profiles and effectively protected blood vessels from atherosclerosis progression in cholesterol-fed rabbits compared with that of fenofibrate and atorvastatin. DATA AVAILABILITY: Additional data can be provided upon reasonable request from the date of publication of this article within 5 years. The request should be sent to the author-correspondent at the address cd95@mail.ru."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOA1 • APOB • FAS